Please ensure Javascript is enabled for purposes of website accessibility

Why Axsome Therapeutics Stock Is On Fire Today

By George Budwell - Dec 16, 2019 at 9:27AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Axsome's clinical pipeline has scored yet another win.

What happened

Axsome Therapeutics (AXSM 9.66%), a clinical-stage biopharmaceutical company developing novel treatments for central nervous system disorders, saw its shares gain as much as 84% in pre-market trading Monday morning.

The spark? Axsome's shares burst higher in pre-market action today in response to a positive late-stage readout for its NMDA receptor antagonist, AXS-05, as a treatment for major depressive disorder (MDD). Major depressive disorder is a serious behavioral disorder that can lead to suicide in extreme cases. Unfortunately, most patients do not adequately respond to the current regimen of therapies on the market, underscoring the need for new treatment options. 

A middle-aged man screaming in excitement while staring at an open laptop computer.

Image source: Getty Images.

So what

Given the documented medical need for more potent MDD therapies, and the fact that a whopping 17 million American adults suffer from this condition every year, according to the National Institutes of Health, this experimental depression med has a clear path toward blockbuster status. That's a big deal for a pre-revenue biotech company with a market cap of less than $3 billion.  

Now what

Axsome plans to submit a New Drug Application for AXS-05's MDD indication in the second half of 2020. That puts a commercial launch -- assuming approval -- on track for early 2021. Meanwhile, the company is slated to announce several additional clinical and regulatory catalysts in the coming months. So, even though Axsome's shares have risen by a staggering 3034% in 2019 (when including today's pre-market move), there's good reason to believe that this red-hot biotech could churn even higher in 2020.  

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Axsome Therapeutics, Inc. Stock Quote
Axsome Therapeutics, Inc.
$26.46 (9.66%) $2.33

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.